Tele: 561.316.3330
Breaking Medical Device News

Thursday, September 23, 2021
HomeMARKET REPORTSWorldwide Prosthetic Heart Valve Market to 2025

Worldwide Prosthetic Heart Valve Market to 2025

January 27, 2021

Worldwide prosthetic heart valve market will show rapid growth due to the subsequent growth in the prevalence of heart valve disease and rising regulatory approvals for a new and advanced prosthetic heart valve.

Valvular heart disease (VHD) places a significant burden on the global healthcare system. According to the American College of Cardiology, there are approximately 5 million Americans that are being diagnosed with HVD every year. VHD mainly affects the older population as a result of calcium buildup and scarring in the valve cusp due to ageing. The prevalence of VHD in the population aged 18-44 and 75 years was 0.7% and 13.0%, respectively in 2012. Therefore the rapid growth in the ageing population and the consequent rise in the prevalence of VHD is expected to drive the market growth for the prosthetic heart valve market.

The prosthetic valves market has also witnessed several clinical trials in recent years especially in the European countries due to uniform regulations and high prevalence of heart diseases.

Companies Mentioned

  • Medtronic PLC
  • Edwards Lifesciences Corporation
  • Boston Scientific Corporation
  • Livanova PLC
  • St. Jude Medical Inc. (An Abbott Laboratories Company)
  • Symetis SA
  • Jenavalve Technology Inc.
  • Cryolife Inc.
  • TTK Healthcare Limited
  • Colibri Heart Valve LLC
  • Lepu Medical Technology Co. Ltd

Key Market Trends

Transcatheter Heart Valve Segment is Expected to Register Robust Growth During the Forecast Period

The transcatheter heart valve segment is expected to hold a significant share in the global market and the large share can be attributed to the various factors such as ease of implantation, rise in the number of transcatheter heart valve surgery centres and growing of the patient population. There are also growth opportunities in emerging countries and the use of transcatheter heart valves for new indications (treatment of intermediate-risk patients and high-risk patients) are thus expected to provide numerous opportunities for the market growth during the forecast period.

In addition, the rise in adoption rate for transcatheter heart valve implantation procedure and new device approvals are expected to lead the growth of transcatheter heart valve market.

North America is Found to be the Largest Market for the Prosthetic Heart Valve

North America is expected to dominate the prosthetic heart valve market, followed by Europe, Asia-Pacific, and the rest of the world. North America contributes to the largest market share due to the rapid growth in the ageing population and the high prevalence of valvular heart diseases. Furthermore, the favourable reimbursement scenario and rising product approvals for the heart valve are also contributing to the growth of the North American prosthetic heart valve market.

The Asia Pacific is also expected to witness the high growth in the next few years, due to the growing incidences of chronic diseases and increasing disposable income.

Competitive Landscape

A majority of the leading players in this market are focusing on marketing and promotional activities, product launches and approvals, acquisitions, agreements, collaborations, and expansions to enhance their market presence and strengthen their distribution networks, cater to the needs of a growing customer base, widen their product portfolios, and boost their production capabilities.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing Prevalence of Heart Valve Disease

4.2.2 Rising Regulatory Approvals for New and Advanced Prosthetic Heart Valve

4.3 Market Restraints

4.3.1 High Cost of Transcatheter Aortic Valve Replacement (TAVR) Procedures

4.3.2 Availability of Alternative Methods for Treating Heart Valve Diseases (HVD)

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Type of Valve

5.1.1 Mechanical Heart Valve

5.1.2 Bioprosthetic Heart Valve

5.1.3 Transcatheter Heart Valve

5.2 By Position

5.2.1 Mitral Valve

5.2.2 Aortic Valve

5.2.3 Other Positions

5.3 Geography

5.3.1 North America

5.3.2 Europe

5.3.3 Asia-Pacific

5.3.4 Middle East & Africa

5.3.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit here.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy